A 51-year-old man with a long-standing history of bileaflet mitral valve prolapse accompanied by mitral annular disjunction and mild mitral regurgitation presented for evaluation of increasingly frequent palpitations. Ambulatory Holter monitoring, cardiac magnetic resonance imaging, serial transthoracic echocardiography, and diagnostic electrophysiology studies were consistent with a diagnosis of arrhythmogenic bileaflet mitral valve prolapse syndrome. Because of the presence of a similar phenotype in the proband's mother, brother, and maternal aunt, research-based whole exome sequencing was pursued and a novel truncating variant (p.Trp34*-FLNC) in the cardiomyopathycausative FLNC-encoded filamin C unearthed that cosegregated with disease. Unexpectedly, these observations provide the first evidence that a heritable proarrhythmic genetic substrate (ie, FLNC haploinsufficiencyemediated weakening of cell-cell adhesion) may underlie, at least in part, some cases of arrhythmogenic mitral valve prolapse syndrome. 
M
itral valve prolapse (MVP) is observed in an estimated 2% to 3% of the general population. 1 Although MVP is largely regarded as a benign condition, the annual rate of sudden cardiac death (SCD) in individuals with MVP (0.2%-0.4% per year) 2 is roughly twice that observed in the general population (0.1%-0.2% per year). 3 Much of this increased SCD risk is attributable to left ventricular dysfunction in the setting of severe mitral regurgitation (MR). 4 However, life-threatening ventricular arrhythmias are still observed in patients with MVP and trivial to mild MR. 5 This phenomenon may be explained, in part, by arrhythmogenic bileaflet MVP syndrome (ABiMVPS), a recently described clinical entity characterized clinically by bileaflet MVP; frequent and complex ventricular arrhythmias, likely secondary to prolapsing leaflet-induced papillary muscle(s) or left ventricle fibrosis; and increased risk of SCD. [6] [7] [8] [9] Furthermore, mitral annular disjunction (MAD), defined as detachment of the mitral annulus from the ventricular myocardium, is associated with papillary muscle fibrosis and ventricular arrhythmia in individuals with and without myxomatous MVP. 10 Thus far, no underlying genetic predisposition for ABiMVPS with or without MAD has been identified.
Genetic variation in FLNC-encoded filamin C (FLNC), an actin-binding protein that is critical for the structural integrity of the sarcomere in cardiac and skeletal muscles, has been linked to dilated 14 and restrictive cardiomyopathy (RCM). [15] [16] [17] In addition, pathogenic variants in FLNA-encoded filamin A, a closely related protein, have been linked to X-linked cardiac valvular dysplasia. 18 However, valvular abnormalities have yet to be documented in individuals with pathogenic variants in FLNC.
Here, we present a case of a 51-year-old man with a personal and family history of bileaflet MVP, posterolateral MAD, ventricular arrhythmia, and mild to moderate left ventricular enlargement. Research-based whole exome sequencing of the proband, a similarly affected maternal aunt, unaffected father, and unaffected brother identified an ultrarare (absent in the 141,456 public exomes and genomes contained in the Genome Aggregation Database) truncating variant (p.Trp34*-FLNC) in FLNC as potential monogenetic substrate underlying a shared ABiMVPS-like clinical phenotype. Figure 1A and B) as well as newly discovered moderate left ventricular enlargement (LVEDD, 63 mm) with preserved left ventricular systolic function (LVEF, 55%) on transthoracic echocardiogram ( Figure 1C ). In addition, a high burden of multifocal premature ventricular contractions (PVCs; 835 ventricular events/h; 16% of total beats), including in a right bundle branch pattern with a superior axis suggestive of a posteromedial papillary muscle (PMPM) origin ( Figure 1E ), occurring singly, in bigeminy, and at times in short runs of nonsustained ventricular tachycardia (NSVT) on 24-hour Holter. Lastly, cardiac magnetic resonance imaging revealed modest delayed enhancement within the inferior and inferolateral base of the left ventricle ( Figure 1D) . Importantly, over the past approximately 7 years, the results of 3 maximal electrocardiogram stress tests and a recent echocardiography stress test have been negative for ischemia.
CASE REPORT
Interestingly, the patient's mother (II.2), older brother (III.2), and maternal aunt (II.3) also had MVP, varying degrees of MAD, frequent PVCs or runs of NSVT, and mild to moderate left ventricular enlargement ( Figure 2A ). However, these echocardiographic and electrocardiographic features were absent in the proband's father (II.1) and the remaining brother (III.1) (Figure 2A ).
Given the patient's family history, tall stature, and mitral valve abnormalities, an underlying connective tissue disease, specifically Marfan syndrome, was considered initially. The patient was evaluated by medical genetics, and on the basis of a "systemic score" of 1, Marfan syndrome was deemed unlikely. No other evidence of an underlying connective tissue disorder (Beighton score, 0), including joint laxity, pectus excavatum, or aortic dilation (by both echocardiography and magnetic resonance angiography), was noted. Further work-up, including commercial genetic testing, for an underlying familial connective tissue disorder, valvular disease, and/or DCM was deferred. Metoprolol and low-dose lisinopril were initiated for the management of symptomatic ventricular ectopy in the setting of a presumed mild nonischemic DCM.
Unfortunately, over the ensuing year, the patient experienced increasingly frequent symptomatic palpitations and presyncopal episodes. Repeated echocardiographic evaluation revealed no substantial changes. Given the ongoing burden of multifocal PVCs, concern for an increased risk of PVCtriggered ventricular fibrillation and SCD in the setting of bileaflet MVP, and potential that the degree of ventricular ectopy (>10% of total beats) may be resulting in PVC-induced cardiomyopathy, the patient was referred to electrophysiology for consideration of a diagnostic electrophysiology study and targeted PVC ablation.
Two predominant PVC morphologies that mapped to the left anterior fascicle and PMPM, respectively, were identified and ablated. The patient initially did well postablation. However, over the ensuing 6 months, the patient once again began to experience increasing palpitations and presyncopal episodes that corresponded with frequent PVCs or runs of NSVT on a 30-day event monitor, predominantly of right bundle branch morphology with an inferior axis ( Figure 1E ), suggestive of an anterolateral papillary muscle (ALPM) origin. Ultimately, a second targeted PVC ablation was pursued and a predominant PVC morphology ( Figure 1E ) that mapped to the ALPM was ablated successfully. Furthermore, mechanical trauma to the left ventricular inflow tract and papillary muscles from the prolapsed and redundant mitral valve leaflets was observed on intracardiac ultrasound. Importantly, no additional consistent PVC morphologies or NSVTs were observed. Because of the persistence of nontargetable PVCs postablation, sotalol was initiated and the need for an implantable cardioverterdefibrillator discussed. Ultimately, given his preserved ejection fraction and absence of hemodynamically significant ventricular arrhythmias, the patient elected close clinical follow-up.
Over the past 5 years, the patient has done well with improvement in symptomatology, PVC burden (85-127 ventricular events/h; 4%-6% of overall beats), and left ventricular systolic function (current LVEF, 61%). Furthermore, no considerable change in the severity of MR (moderate) or degree of left ventricular enlargement (current LVEDD, 62 mm) has been observed.
METHODS AND RESULTS
Given the unique familial ABiMVPS-like phenotype (bileaflet MVP with frequent multifocal PVCs), the patient was referred for research-based genetic testing. This study was conducted after approval was obtained from the Mayo Clinic Institutional Review Board.
Whole exome sequencing was performed on the proband, affected maternal aunt, and 2 unaffected first-degree relatives (Figure 2A ). Variants were filtered by minor allele frequency (<0.0005) in the Genome Aggregation Database and functional impact before analysis under an autosomal dominant model using Ingenuity Variant Analysis (QIAGEN) as outlined in Figure 2B . The 8 remaining variants (Table) were confirmed in the proband by Sanger sequencing and prioritized using ToppGene and Endeavour algorithms as previously described. 19 After filtering and gene ranking, the topranking candidate gene was FLNC. Sanger sequencing was used to confirm the presence of p.Trp34*-FLNC (c.201G>AeFLNC) in the proband and his affected maternal aunt ( Figure 2C ) and its absence in both his unaffected father and unaffected brother ( Figure 2D ). Unfortunately, DNA samples for the proband's deceased affected mother (died at the age of 79 of complications of severe disseminated intravascular coagulation) and affected older brother (declined participation in genetic studies) were not available for research-based genetic testing.
DISCUSSION
In this molecular case report, we report, for the first time, the identification of a familial ABiMVPS-like phenotype and the subsequent use of whole exome sequencing to implicate a truncating variant (p.Trp34*-FLNC) in the muscle-specific FLNC-encoded filamin C as a potential proarrhythmic genetic substrate for ABiMVPS. Previously, nonsynonymous genetic variation in FLNC has been implicated in 3 cardiacrestricted phenotypes (DCM, [11] [12] [13] HCM, 14 and RCM [15] [16] [17] ) ( Figure 3A ). Missense variants, localizing to the actin-binding and rod domains, are observed predominantly in HCM and RCM in which they appear to disrupt filamin C dimerization, actin cross-linking, and/ or subcellular localization, resulting in the formation of aberrant, and likely cytotoxic, protein aggregates in explanted hearts, heterologous expression systems, and a zebrafish overexpression model ( Figure 3B) . 14, 16, 17 In contrast, nonsense mutations, expected to cause FLNC haploinsufficiency secondary to nonsense-mediated decay, have been observed predominantly in DCM and on the basis of insights gleaned from explanted hearts and murine and zebrafish models appear to weaken coupling of the Z-disc and sarcomere to adjacent cardiomyocytes (at intercalated discs) and the sarcolemma and extracellular matrix (at costameres) ( Figure 3C ).
11-13 Impaired cell-cell mechanotransduction, particularly at sites subjected to increased mechanical force(s), likely leads to left ventricular dysfunction, diffuse myocardial fibrosis, ventricular arrhythmias, and increased risk of SCD that defines so-called FLNC-mediated "left dominant" arrhythmogenic DCM. [11] [12] [13] Although mild to moderate left ventricular dilation and ventricular arrhythmias observed in the small p.Trp34*-FLNC kindred detailed in this report are consistent with FLNC-mediated arrhythmogenic DCM, no marked valvular abnormalities, including MVP, have been reported in individuals with disease-causative FLNC variants. Unlike the closely related FLNA-encoded filamin A, which is ubiquitously expressed and underlies nonsyndromic X-linked mitral valve dysplasia, FLNC expression is limited to striated muscle. Therefore, unless p.Trp34*-FLNC confers a novel effect in endothelial and valvular interstitial cells, it seems unlikely that FLNC is directly responsible for MVP observed in this kindred.
However, the presence of complex ventricular ectopy arising from ALPM, PMPM, and fascicular foci ( Figure 1D and E) and pattern of left ventricular delayed enhancement on cardiac magnetic resonance imaging ( Figure 1C) suggest that left ventricular papillary muscle and inferobasal myocardial fibrosis serve as the primary arrhythmogenic substrates. Indeed, the combination of right bundle branch block ectopy or arrhythmias, inferobasal left ventricular delayed enhancement, and bileaflet MVP observed in the proband is consistent with the established pathophysiology of ABiMVPS. 6, 9 Furthermore, with the postablation reduction in PVC burden (from 16% to 4%-6% of total beats), the proband's ventricular dysfunction has improved and remained remarkably stable, suggesting that PVC-induced cardiomyopathy may have been a contributing factor.
As such, this case raises the possibility that some cases of ABiMVPS may follow a "2-hit" model in which an underlying arrhythmogenic genetic substrate that weakens myocyte coupling (in this case, FLNC haploinsufficiency) is awakened or exacerbated by the excess force generated by the prolapsing leaflet(s) of genetically unrelated MVP with MAD. Such a scenario would explain why (1) most patients with uncomplicated myxomatous MVP do not develop potentially life-threatening ventricular arrhythmias and (2) no family history of MVP plus arrhythmia or SCD has been described in the literature on ABiMVPS to date.
Ultimately, further studies are needed to determine whether ABiMVPS represents a form of focal arrhythmogenic cardiomyopathy
